Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512943 | 0.82 | RCE1 (0.49) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL29118548 | 0.81 | TSHR (0.41) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL28246143 | 0.81 | RCE1 (0.50) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL7814719 | 0.81 | RCE1 (0.44) | RCE1HTTKMT2ANPC1TSHR | |
| SCHEMBL27382395 | 0.80 | TSHR (0.40) | RCE1HTTKMT2AMAPTTSHR | |
| SCHEMBL21677653 | 0.79 | RCE1 (0.49) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL6512934 | 0.79 | ALDH1A1 (0.43) | RCE1KMT2ANPC1TSHRSLC1A3 | |
| SCHEMBL5566637 | 0.78 | RCE1 (0.51) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL10528179 | 0.78 | RCE1 (0.48) | RCE1HTTKMT2ANPC1MAPT | |
| SCHEMBL26601450 | 0.78 | TSHR (0.52) | RCE1HTTKMT2ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691814-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-1474425-B9 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1707566-A1 | Deazapurines and uses thereof | Eisai Co., Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1474425-B1 | DEAZAPURINES AND USES THEREOF | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050124649-A1 | Deazapurines and uses thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1474425-A1 | DEAZAPURINES AND USES THEREOF | Eisai Co. Ltd. (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | RCE1 1935/4885HTT 4769/4885KMT2A 1590/4885 |
| US-20050124649-A1 | Deazapurines and uses thereof | TPMT, CD38, CD2 | RCE1 1925/4885HTT 4766/4885KMT2A 1654/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | RCE1 1580/4885HTT 4573/4885KMT2A 963/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | RCE1 1520/4885HTT 4859/4885KMT2A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.